Download PDF
Thromb Haemost 1999; 81(05): 845-846
DOI: 10.1055/s-0037-1614580
Letters to the Editor
Schattauer GmbH

Oral Contraceptive Users and Screening of Factor V Leiden

Justo Aznar
1   From the Departments of Clinical Pathology
,
Juan Gilabert
2   Obstetrics and Gynecology, University Hospital “La Fe”, Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 22 October 1998

Accepted 18 January 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Herrmann FH, Koesling M, Schröder W, Altman R, Jiménez R, Lopaciuk S, Pérez-Requejo JL, Singh JR. Prevalence of factor V Leiden mutation in various populations.. Genet Epidemiol 1997; 14: 403-11.
    CrossrefPubMedGoogle Scholar
  • 2 Venous thromboembolic disease and combined oral contraceptives: results of the international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.. Lancet 1995; 346:: 1575-82.
    CrossrefPubMedGoogle Scholar
  • 3 Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy.. Arch Intern Med 1997; 157: 1522-30.
    CrossrefPubMedGoogle Scholar
  • 4 Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.. Ann Intern Med 1997; 127: 895-903.
    PubMedGoogle Scholar
  • 5 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.. Lancet 1995; 346: 1593-6.
    CrossrefPubMedGoogle Scholar
  • 6 Rossendaal FR. Oral contraceptives and screening of factor V Leiden (Letter).. Thromb Haemost 1996; 75: 524-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ 1996; 313: 1127-30.
    CrossrefPubMedGoogle Scholar
  • 8 Altés A, Souto JC, Mateo J, Borrell M, Fontcuberta J. Activated protein C resistance assay when applied in the general population.. Am J Obstet Gynecol 1997; 176: 358-9.
    CrossrefPubMedGoogle Scholar
  • 9 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation.. Lancet 1994; 344: 1453-7.
    CrossrefPubMedGoogle Scholar
  • 10 Jorquera JL, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance.. Lancet 1994; 344: 1162-3.
    PubMedGoogle Scholar
  • 11 Prandoni P, Lensing AWA, Cogo A, Cuppini SS, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep vein thrombosis.. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 12 Szucs T, Osterkorn D, Schramm W. Gesundheitsökonomische Evaluation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern.. Med Klin 1996; 91: 317-9.
    PubMedGoogle Scholar